SCHEMBL248690

SCHEMBL248690

NNc1ccnc2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.63
ADRA1D P25100 2/20 0.63
ADRA1A P35348 2/20 0.63
ADRA1B P35368 2/20 0.63
FERMT2 Q96AC1 1/20 0.61
NCF1 P14598 1/20 0.55
LOXL2 Q9Y4K0 1/20 0.52
PTPN1 P18031 1/20 0.51
PTPN11 Q06124 1/20 0.51
FADS1 O60427 1/20 0.50
EGFR P00533 1/20 0.50
ERBB2 P04626 1/20 0.50
HTT P42858 2/20 0.49
RIPK2 O43353 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
HRH3 Q9Y5N1 1/20 0.46
GAK O14976 1/20 0.46
COQ8A Q8NI60 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL695985 0.98 HTR1A (0.61) HTR1AADRA1DADRA1AADRA1BFERMT2
Hydrochloric Acid SCHEMBL696334 0.98 HTR1A (0.61) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL2478157 0.86 MEN1 (0.57) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL30504562 0.86 MEN1 (0.57) HTR1AADRA1DADRA1AADRA1BFERMT2
Hydrochloric Acid SCHEMBL28828326 0.84 MEN1 (0.56) HTR1AADRA1DADRA1AADRA1BFERMT2
Hydrochloric Acid SCHEMBL6311928 0.84 MEN1 (0.56) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL6752938 0.83 HTR1A (0.68) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL29005643 0.80 NPC1 (0.49) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL4500702 0.79 HTR1A (0.63) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL9902520 0.79 HTR1A (0.63) HTR1AADRA1DADRA1AADRA1BFERMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4103946-B1 IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME IMMUNDIAGNOSTIK AG (DE) 2024-03-13 EP claimed
US-20230109016-A1 IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME IMMUNDIAGNOSTIK AG (DE) 2023-04-06 US claimed
EP-4103946-A1 IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME Immundiagnostik AG (DE) 2022-12-21 EP claimed
WO-2021160696-A1 IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME IMMUNDIAGNOSTIK AG (DE) 2021-08-19 WO claimed
US-3996231-A ANTIINFLAMMATORY, ANALGESICS CHOAY S.A. (FR) 1976-12-07 US claimed
EP-4596537-A1 NOVEL FLUORENE DERIVATIVE COMPOUND AND USE THEREOF JD Bioscience Inc. (KR) 2025-08-06 EP disclosed
CN-119552120-A Pyrazole and imidazole compounds for inhibiting IL-17 and rory 里亚塔医药公司 2025-03-04 CN disclosed
CN-112654610-B Pyrazole and imidazole compounds for inhibiting IL-17 and rory 里亚塔医药公司 2024-12-24 CN disclosed
US-20240398783-A1 Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof GISMO THERAPEUTICS, INC. 2024-12-05 US disclosed
US-20240360084-A1 PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA REATA PHARMACEUTICALS INC (US) 2024-10-31 US disclosed
EP-3558969-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-09-18 EP disclosed
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-09-03 US disclosed
WO-1997010215-A1 FUNGICIDAL QUINOLINES BASF AKTIENGESELLSCHAFT (DE) 1997-03-20 WO disclosed
EP-0304239-B1 Reformed polysilazane and method of producing same TOA NENRYO KOGYO KK (JP) 1995-04-19 EP disclosed
US-4975512-A Crosslinking with amine, ammonium, hydrazine PETROLEUM ENERGY CENTER (JP) 1990-12-04 US disclosed
US-4880818-A 1-Acyl-4-[1-(4-quinolinyl)-hydrazin-2-ylidene]piperidines and their use as hypotensive agents HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1989-11-14 US disclosed
US-4771052-A Tetrahydropyrido[3',4':4,5]pyrrolo[2,3-c]quinolines and their use as hypotensive agents HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1988-09-13 US disclosed
EP-0277625-A2 Tetrahydropyrido[3',4':4,5]pyrrolo[2,3-c]quinolines, intermediates and a process for the preparation thereof and their use as hypotensive agents HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1988-08-10 EP disclosed
US-3996231-A ANTIINFLAMMATORY, ANALGESICS CHOAY S.A. (FR) 1976-12-07 US disclosed
US-3936444-A FROM A LACTIM-ETHER AND AN ARYL OR HETEROARYL HYDRAZINE, ACID CATALYST BAYER AKTIENGESELLSCHAFT (DT) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240398783-A1 Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof PRNP, GBA1, GBA3 HTR1A 1008/4885ADRA1D 3806/4885ADRA1A 3536/4885
US-20240360084-A1 PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA RORC, RORB, RORA HTR1A 4525/4885ADRA1D 1471/4885ADRA1A 1173/4885
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 HTR1A 2942/4885ADRA1D 2840/4885ADRA1A 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.